Impact of the implementation of the Intelligent Antimicrobial System (iAMS) on clinical outcomes among patients with bacteraemia caused by methicillin-resistant Staphylococcus aureus.
Journal
International journal of antimicrobial agents
Series/Report No.
International Journal of Antimicrobial Agents
Journal Volume
63
Journal Issue
5
ISSN
1872-7913
Date Issued
2024-05
Author(s)
Ho, Lu-Ching
Yu Chi, Chih
You, Ying-Shu
Hsieh, Yow-Wen
Hou, Yu-Chi
Lin, Tzu-Ching
Chen, Ming Tung
Chou, Chia-Hui
Chen, Yu-Chieh
Hsu, Kai-Cheng
Yu, Jiaxin
Cho, Der-Yang
DOI
10.1016/j.ijantimicag.2024.107142
Abstract
Objectives: This study aimed to investigate the clinical impact of the Intelligent Antimicrobial System (iAMS) on patients with bacteraemia due to methicillin-resistant (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA). Methods: A total of 1008 patients with suspected SA infection were enrolled before and after the implementation of iAMS. Among them, 252 with bacteraemia caused by SA, including 118 in the iAMS and 134 in the non-iAMS groups, were evaluated. Results: The iAMS group exhibited a 5.2% (from 55.2% to 50.0%; P = 0.96) increase in the 1-year survival rate. For patients with MRSA and MSSA compared to the non-iAMS group, the 1-year survival rate increased by 17.6% (from 70.9% to 53.3%; P = 0.41) and 7.0% (from 52.3% to 45.3%; P = 0.57), respectively, both surpassing the rate of the non-iAMS group. The iAMS intervention resulted in a higher long-term survival rate (from 70.9% to 52.3%; P = 0.984) for MRSA patients than for MSSA patients. MRSA patients experienced a reduced length of hospital stay (from 23.3% to 35.6%; P = 0.038), and the 45-day discharge rate increased by 20.4% (P = 0.064). Furthermore, the intervention resulted in a significant 97.3% relative decrease in near miss medication incidents reported by pharmacists (P = 0.013). Conclusions: Implementation of iAMS platform improved long-term survival rates, discharge rates, hospitalization days, and medical cost (although no significant differences were observed) among patients with MRSA bacteraemia. Additionally, it demonstrated significant benefits in ensuring drug safety.
Subjects
Antimicrobial resistance
Bacteraemia
Clinical decision support system
Intelligent Antimicrobial System
Medical AI platform
Staphylococcus aureus
SDGs
Publisher
Elsevier B.V.
Description
Article number 107142
Type
journal article